NasdaqGS:TWSTBiotechs
Assessing Twist Bioscience (TWST) Valuation After New Invenra Bispecific Antibody Licensing Deal
Twist Bioscience (TWST) is back in focus after announcing a licensing deal with Invenra that brings the B-Body bispecific antibody platform under a co-exclusive arrangement, directly expanding Twist’s antibody discovery service offering.
See our latest analysis for Twist Bioscience.
The licensing news lands after a strong run, with the latest share price at $46.92, a 30 day share price return of 11.69% and a 90 day share price return of 46.58%. Looking further out, the stock shows a 1 year...